Latest News and Press Releases
Want to stay updated on the latest news?
-
SEATTLE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 400 employers and millions of members, will participate in the Credit Suisse 30th...
-
Fiscal second quarter 2022 revenue of $73.3 million, a 99% increase compared to fiscal second quarter 2021 revenue of $36.8 million Introduced Personalized Healthcare category, focused on human...
-
SEATTLE, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal second quarter 2022 financial results on Thursday, October 7, 2021, after the...
-
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, will participate in the following...
-
SEATTLE, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, will participate in the 41st Annual...
-
Fiscal first quarter 2022 revenue of $59.5 million, a 66% increase compared to fiscal first quarter 2021 revenue of $35.9 million Company raises guidance for fiscal year 2022 to $300 million - $305...
-
SEATTLE, June 17, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, today announced that it will release...
-
Accolade to begin offering virtual primary care and mental health consultations directly to members. $200bn+ combined total addressable market materially expands opportunity to reinvent healthcare...
-
SEATTLE, June 01, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, will participate in the following upcoming...
-
SEATTLE, May 10, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, will participate in the following upcoming...